Cargando…
A Journey with LGMD: From Protein Abnormalities to Patient Impact
The limb-girdle muscular dystrophies (LGMD) are a collection of genetic diseases united in their phenotypical expression of pelvic and shoulder area weakness and wasting. More than 30 subtypes have been identified, five dominant and 26 recessive. The increase in the characterization of new genotypes...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190568/ https://www.ncbi.nlm.nih.gov/pubmed/34110586 http://dx.doi.org/10.1007/s10930-021-10006-9 |
_version_ | 1783705711756181504 |
---|---|
author | Georganopoulou, Dimitra G. Moisiadis, Vasilis G. Malik, Firhan A. Mohajer, Ali Dashevsky, Tanya M. Wuu, Shirley T. Hu, Chih-Kao |
author_facet | Georganopoulou, Dimitra G. Moisiadis, Vasilis G. Malik, Firhan A. Mohajer, Ali Dashevsky, Tanya M. Wuu, Shirley T. Hu, Chih-Kao |
author_sort | Georganopoulou, Dimitra G. |
collection | PubMed |
description | The limb-girdle muscular dystrophies (LGMD) are a collection of genetic diseases united in their phenotypical expression of pelvic and shoulder area weakness and wasting. More than 30 subtypes have been identified, five dominant and 26 recessive. The increase in the characterization of new genotypes in the family of LGMDs further adds to the heterogeneity of the disease. Meanwhile, better understanding of the phenotype led to the reconsideration of the disease definition, which resulted in eight old subtypes to be no longer recognized officially as LGMD and five new diseases to be added to the LGMD family. The unique variabilities of LGMD stem from genetic mutations, which then lead to protein and ultimately muscle dysfunction. Herein, we review the LGMD pathway, starting with the genetic mutations that encode proteins involved in muscle maintenance and repair, and including the genotype–phenotype relationship of the disease, the epidemiology, disease progression, burden of illness, and emerging treatments. |
format | Online Article Text |
id | pubmed-8190568 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-81905682021-06-10 A Journey with LGMD: From Protein Abnormalities to Patient Impact Georganopoulou, Dimitra G. Moisiadis, Vasilis G. Malik, Firhan A. Mohajer, Ali Dashevsky, Tanya M. Wuu, Shirley T. Hu, Chih-Kao Protein J Article The limb-girdle muscular dystrophies (LGMD) are a collection of genetic diseases united in their phenotypical expression of pelvic and shoulder area weakness and wasting. More than 30 subtypes have been identified, five dominant and 26 recessive. The increase in the characterization of new genotypes in the family of LGMDs further adds to the heterogeneity of the disease. Meanwhile, better understanding of the phenotype led to the reconsideration of the disease definition, which resulted in eight old subtypes to be no longer recognized officially as LGMD and five new diseases to be added to the LGMD family. The unique variabilities of LGMD stem from genetic mutations, which then lead to protein and ultimately muscle dysfunction. Herein, we review the LGMD pathway, starting with the genetic mutations that encode proteins involved in muscle maintenance and repair, and including the genotype–phenotype relationship of the disease, the epidemiology, disease progression, burden of illness, and emerging treatments. Springer US 2021-06-10 2021 /pmc/articles/PMC8190568/ /pubmed/34110586 http://dx.doi.org/10.1007/s10930-021-10006-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Georganopoulou, Dimitra G. Moisiadis, Vasilis G. Malik, Firhan A. Mohajer, Ali Dashevsky, Tanya M. Wuu, Shirley T. Hu, Chih-Kao A Journey with LGMD: From Protein Abnormalities to Patient Impact |
title | A Journey with LGMD: From Protein Abnormalities to Patient Impact |
title_full | A Journey with LGMD: From Protein Abnormalities to Patient Impact |
title_fullStr | A Journey with LGMD: From Protein Abnormalities to Patient Impact |
title_full_unstemmed | A Journey with LGMD: From Protein Abnormalities to Patient Impact |
title_short | A Journey with LGMD: From Protein Abnormalities to Patient Impact |
title_sort | journey with lgmd: from protein abnormalities to patient impact |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190568/ https://www.ncbi.nlm.nih.gov/pubmed/34110586 http://dx.doi.org/10.1007/s10930-021-10006-9 |
work_keys_str_mv | AT georganopouloudimitrag ajourneywithlgmdfromproteinabnormalitiestopatientimpact AT moisiadisvasilisg ajourneywithlgmdfromproteinabnormalitiestopatientimpact AT malikfirhana ajourneywithlgmdfromproteinabnormalitiestopatientimpact AT mohajerali ajourneywithlgmdfromproteinabnormalitiestopatientimpact AT dashevskytanyam ajourneywithlgmdfromproteinabnormalitiestopatientimpact AT wuushirleyt ajourneywithlgmdfromproteinabnormalitiestopatientimpact AT huchihkao ajourneywithlgmdfromproteinabnormalitiestopatientimpact AT georganopouloudimitrag journeywithlgmdfromproteinabnormalitiestopatientimpact AT moisiadisvasilisg journeywithlgmdfromproteinabnormalitiestopatientimpact AT malikfirhana journeywithlgmdfromproteinabnormalitiestopatientimpact AT mohajerali journeywithlgmdfromproteinabnormalitiestopatientimpact AT dashevskytanyam journeywithlgmdfromproteinabnormalitiestopatientimpact AT wuushirleyt journeywithlgmdfromproteinabnormalitiestopatientimpact AT huchihkao journeywithlgmdfromproteinabnormalitiestopatientimpact |